Avexa Limited Wins $4.3M Commercial Ready Grant for Anti-HIV Drug Discovery Program
MELBOURNE, Australia--(BUSINESS WIRE)--Avexa (ASX:AVX) announced today that it has been awarded an Australian Government Commercial Ready Grant worth $4.3m AUD to develop a new generation of HIV antiviral drugs using ‘fragment based drug design,’ a non-traditional research methodology. Avexa will work with CSIRO’s Molecular and Health Technologies division to discover inhibitors of the HIV integrase enzyme which conventional techniques are unable to identify. This program can also be applied to other antiviral targets.